Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
SHANGHAI, China and SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) approved Kezar's investig...
Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
--VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU-- SHANGHAI, Feb. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s partner Pfizer Inc. (NYSE: PFE) announced that the ...
Everest Medicines' Licensing Partner Venatorx Pharmaceuticals Announces Publication of Positive Results from Cefepime-Taniborbactam's Phase 3 CERTAIN-1 Study in New England Journal of Medicine
--Cefepime-taniborbactam was superior to meropenem for the composite efficacy endpoint with composite efficacy sustained at late follow-up visit-- SHANGHAI, Feb. 21, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK)'s licensing partner, Venatorx Pharmaceuticals announced that The New England ...
Everest Medicines Announces Termination of Collaboration Agreements with Providence
-Everest will continue to develop self-discovered products utilizing the mRNA platform- SHANGHAI, Feb. 19, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative...
Everest Medicines Announces 2023 Revenue Expected to be Between RMB124 Million and RMB126 Million
SHANGHAI, Jan. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the Company expects to record a total reven...
Everest Medicines' Partner Calliditas Therapeutics Announces Nefecon® the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline
SHANGHAI, Dec. 21, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced that the U.S. Food and Drug Administration (FDA) had approved Nefecon® delayed rele...
Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China
-- Everest plans to contribute to the ongoing global Phase 2b PALIZADE trial of zetomipzomib in active lupus nephritis – -- Zetomipzomib demonstrated clinically meaningful renal responses with a favorable tolerability profile in an earlier Phase 2 trial -- -- Renal and autoimmune diseases are k...
Everest Medicines Announces Positive Topline Results from Induction Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderate-to-Severe Active Ulcerative Colitis
--Clinically meaningful and statistically significant results demonstrated for primary endpoint and key secondary endpoints for the 12-week induction period-- --Etrasimod was well-tolerated and its safety profile was consistent with prior studies-- --Everest will advance the late-stage study as...
Everest Medicines Announces Acceptance of Nefecon® New Drug Applications for the Treatment of Primary IgA Nephropathy in Adult Patients in South Korea
SHANGHAI, Nov. 30, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that its New Drug Application (NDA) for Nefecon®...
Everest Medicines Announces China NMPA's Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients
--Nefecon® is the first approved medicine with an IgAN indication in China-- --The approval marks a new era of IgAN treatment for Chinese patients-- SHANGHAI, Nov. 24, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the ...
Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy
SHANGHAI, Oct. 27, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the Pharmaceutical Administration Bureau of...
Everest Medicines Announces Poster Presentation at ASN Kidney Week on Nefecon® Chinese Patient Data and to Hold Conference Calls
SHANGHAI, Oct. 27, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced that it will make a late-breaking poster present...
Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis
SHANGHAI, Oct. 16, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug Administration (FDA) for VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (...
Everest Medicines' Partner Calliditas Presents New Data from the NefIgArd Phase 3 Trial at the 17th International Symposium on IgA Nephropathy Tokyo 2023
SHANGHAI, Oct. 5, 2023 /PRNewswire/ -- Everest Medicines' (HKEX 1952.HK, "Everest", or the "Company") partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") presented new biomarker and subgroup analyses from Nefecon®'s Phase 3 NefIgArd study in both posters and ...
Everest Medicines Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients
SHANGHAI, Sept. 28, 2023 /PRNewswire/ -- Everest Medicines
Everest Medicines Enters into Collaboration and License Agreement with Kezar Life Sciences to Develop and Commercialize Zetomipzomib in Greater China and other Asian Markets
SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today it has entered into a collaboration and license...
Everest Medicines Announces China Center for Drug Evaluation of NMPA Recommends Priority Review for Cefepime-Taniborbactam for the Treatment of Complicated Urinary Tract Infections, including Pyelonephritis
SHANGHAI, Sept. 20, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing, manufacturing, and commercializing transformative pharmaceutical products and vaccines inGreater China and other parts of Asia, announced today that the Center for Drug E...
Everest Medicines Announces New Drug Application Acceptance by the Pharmaceutical Administration Bureau of Macao for Nefecon® for the Treatment of Primary IgA Nephropathy
SHANGHAI, Aug. 25, 2023 /PRNewswire/ -- Everest Medicines
Everest Medicines Announces Interim Results for First Half of 2023
SHANGHAI, Aug. 24, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2023, ...
Everest Medicines Announces Partner Calliditas Therapeutics Receives FDA Priority Review for Full Approval of Nefecon® for the Treatment of IgA Nephropathy
SHANGHAI, Aug. 21, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced today that U.S. Food and Drug Administration (FDA) has accepted the submission for the supplemental New Drug Application (sNDA) for Nefecon® from its partner Calliditas Therapeutics AB ...
